Scientists discover that no two tumors of deadliest form of breast cancer are alike

An international team of scientists mapped the genomes of 100 triple negative breast cancer tumors, the deadliest form of the disease, and discovered that no two genomes were similar. “Seeing these tumors at a molecular level has taught us we’re dealing with a continuum of different types of breast cancer here, not just one,” Steven Jones, co-author of this study, said. “The genetic diversity of these tumors, even though they’re clinically similar, probably explains why they are so difficult to treat.” Triple negative breast cancer does not have surface cell receptors for estrogen, progesterone and herceptin, all linked to breast cancer. Of women who develop breast cancer, 16 percent will have triple negative breast cancer. It is considered the most deadly form because it does not respond well to modern drug therapies, which target those receptors. 

Companies
1
Patents
1
0 Comments
Related Articles
Ann Conkle
Mar 23, 2012
Mayo Clinic-TGen study role testosterone may play in triple negative breast cancer
Preliminary results of a Mayo Clinic - Translational Genomics Research Institute (TGen) collaborative study shows the testosterone receptor may be... Read More
Ann Conkle
Mar 27, 2012
VIDEO - GE healthymagination winner uses the power of the web to further breast cancer treatment
In September 2011, GE launched the $100 million healthymagination challenge, an innovation challenge to find and fund the best new... Read More
New study connects long-term use of estrogen therapy to higher breast cancer risk
A new study has linked the long-term use of both estrogen plus progesterone and estrogen-only hormone therapy (HT) with a... Read More